Washington Entrepreneurial Research Evaluation and Commercialization Hub

华盛顿创业研究评估和商业化中心

基本信息

批准号：
10475213
负责人：
RODNEY J.Y. HO
金额：
$ 99.45万
依托单位：
UNIVERSITY OF WASHINGTON
依托单位国家：
美国
项目类别：
财政年份：
2019
资助国家：
美国
起止时间：
2019-09-23 至 2024-08-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10475213
关键词：
Acquired Immunodeficiency Syndrome Biological Sciences Biomedical Research Biotechnology Businesses Child Cities Climacteric Collaborations Communities Databases Development Drug Interactions Environment Evaluation Research Expenditure Fostering Foundations Fred Hutchinson Cancer Research Center Fruit Funding Gardasil Generations Genetic Genetic Engineering Goals Governing Board Health Health Alliance Health Sciences Hepatitis B Vaccines Hepatitis B Virus Human Papillomavirus Individual Industry Infectious Diseases Research Infrastructure Institutes Institution Insulin Intellectual Property International Investments Lead Leadership Legal Legal patent Licensing Market Research Marketing Medical Device Mentors Mentorship Outcome Pacific Northwest Pathway interactions Persons Pharmacologic Substance Process Protein Engineering Public Health Recombinant Proteins Recombinants Recording of previous events Research Research Institute Research Personnel Research Support Resources Schools Scientist Services Somatotropin Somatropin Structure System Talents Technology Technology Transfer Therapeutic Training Translational Research Translations United States United States National Institutes of Health Universities Vaccines Washington Work Yeasts base burden of illness clinical development commercialization design disability global health health economics health organization improved innovation next generation polypeptide product development professor programs success translational health science

项目摘要

The University of Washington and the entrepreneurial community seeks to partner with the National Institutes of Health to become a Research Evaluation and Commercialization Hub (REACH) to accelerate academic biomedical discoveries into products helping ease the highest U.S. burden of disease and disability. The UW is a powerhouse in health sciences, technology, and innovation in a city known for seeking solutions to the most pressing health problems around the world. The University’s long-standing relationship with the entrepreneurial business community has helped in the formation of Boeing, Microsoft, Amazon, Immunex, Zymogenetics, Teblos, the Drug Interaction Database, and Seattle Genetics. It’s also led to well-recognized recombinant therapeutic and vaccine products such as growth hormone, insulin, RecombiVax HB®, and Gardasil®. Many of our graduates work at major health organizations in the city, including The Gates Foundation, Path, Fred Hutchinson Cancer Research Center, the Infectious Disease Research Institute. The University’s Foster School of Business gathers business leaders to judge and mentor solutions to health problems, and major business leaders are part of the governing board of these organizations and the networking hub The Washington Global Health Alliance and The Innovation Hub of Life Sciences Washington. In this rich spirt of collaboration, a hub to accelerate promising biomedical discoveries would fit right in. A hub is needed to further energize the spirit of discovery and collaboration and overcome barriers in getting products to the public. A hub will leverage existing resources for translational research and support the journey to fruition to innovative products that change lives. With institutional co-funding commitments, strong support of community leaders, and proven leadership in entrepreneurial startups, the four Aims of this proposal are to (1) Develop an integrated infrastructure and implementation system; (2) Identify the most promising technologies, and increase their availability using milestone-driven gap funding and mentoring (in business, marketing, and networking) for market-driven proof-of-product concept and product definition; (3) Fuel the formation of new biotechnology, pharmaceutical, and medical device companies, and assist in pathways to a self-sustaining structure; (4) Train the next generation of biomedical entrepreneurs to lead these ventures. With NIH support, this hub will accelerate the creation of small businesses using biomedical discoveries to launch products that impact health outcomes. An investment in the Pacific Northwest will amplify the returns on this funding due to the critical mass of investigators, and the will of our institutions to make this happen.

华盛顿大学和企业家社区试图与国立研究所合作健康成为研究评估和商业化中心（覆盖范围），以加速学术生物医学发现产品，有助于缓解美国最高的疾病和残疾燃烧。 UW是一个以寻求解决方案而闻名的城市健康科学，技术和创新的强大力量对于世界上最紧迫的健康问题。该大学与企业家界的长期关系有所帮助波音，微软，亚马逊，侵犯，Zymogenetics，Teblos，药物相互作用数据库的形成和西雅图遗传学。这也导致了公认的重组治疗和疫苗产品，例如生长马酮，胰岛素，RebombivaxHB®和Gardasil®。我们的许多毕业生在城市的主要卫生组织中工作，包括盖茨基金会，路径，传染病研究所弗雷德·哈钦森癌症研究中心。大学的寄养商学院收集业务领导者来判断和心理解决方案，以解决健康问题，主要业务领导者是这些组织的理事委员会的一部分，网络中心华盛顿全球卫生联盟和生命科学的创新枢纽华盛顿。本着这种丰富的合作精神，加速有前途的生物医学发现的枢纽将适合。需要进一步激发发现和协作的精神，并克服获取产品的障碍向公众。枢纽将利用现有资源进行转化研究，并支持前往的旅程对改变生活的创新产品的成果。具有机构共同资助的承诺，对社区领导者，以及在企业家创业公司中具有良好的领导才能，该提案的四个目标是（1）开发集成的基础架构和实施系统；（2）确定最有前途的技术，并使用里程碑驱动的差距资金和心理增加（业务，营销和网络）用于市场驱动的产品证明概念和产品定义；（3）为新的形成加油生物技术，制药和医疗设备公司，并协助建立自我维持的途径结构; （4）训练下一代生物医学企业家领导这些企业。在NIH的支持下，该枢纽将使用生物医学发现加速小型企业启动影响健康结果的产品。对西北太平洋的投资将放大回报由于调查人员的关键质量以及我们机构实现这一目标的意愿。